The company will expand its existing Active Pharmaceutical Ingredient (API) production facility in Denmark for the future portfolio within serious chronic diseases, and build a new multi-product manufacturing facility
Novo Nordisk Danish headquarters in Bagsværd, Denmark. (Credit: Novo Nordisk A/S)
Danish pharmaceutical company Novo Nordisk has unveiled its plans to invest DKK15.9bn ($2.3bn) starting this year to boost its manufacturing operations in Denmark.
The company will expand its existing Active Pharmaceutical Ingredient (API) production facility in Denmark for the future portfolio within serious chronic diseases.
It will also build a new multi-product manufacturing facility, covering around 65,000m2 area.
The new facility will be designed with maximum flexibility to accommodate new processes and feature advanced technology and a working environment.
Also, the facility will be designed as a future-proof and cost-effective facility, focused on optimal and compact process flows to reduce water and energy consumption.
The healthcare company has already started construction and the new multi-product manufacturing facility is expected to start production by early 2029.
Novo Nordisk said the investment follows the 100th anniversary of its founding in Denmark.
The company employs more than 21,000 people in Denmark, which accounts for around half of its global workforce.
The investment in Denmark will enhance its production capacity, increase its ability to meet future demand and enable the development of its future clinical late-phase product portfolio.
Once the construction is completed and the facility is fully equipped, the expansion project is anticipated to create 340 new jobs, said the Danish drugmaker.
Novo Nordisk product supply, quality and IT executive vice president Henrik Wulff said: “This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide.
“The investment announced today confirms Hillerød and Denmark as cornerstones in our global footprint, and I would like to take this opportunity to thank the Danish Government and Parliament for their continued focus on ensuring good and stable infrastructure and supplies.”
In December 2021, Novo Nordisk announced more than $2.5bn investment to build three new production facilities and expand the existing facility at its Kalundborg production site in Denmark.